What Kyleena Treats: Main Uses and Benefits

Kyleena is primarily used to provide long-term contraception by addressing the clinical risk of unwanted pregnancy. Its key therapeutic benefit is its role in providing continuous, long-acting protection for up to five years, which contributes to simplifying the contraceptive routine. The system is commonly used to help manage the risk of unwanted pregnancy, provide continuous protection, and support the management of symptoms associated with heavy menstrual bleeding.

The system supports the management of symptoms related to the menstrual cycle, such as heavy or frequent menstrual bleeding. The system may assist with a reduction in blood loss over time, helping ease the overall symptom burden of bleeding. In some patients, this may progress to the absence of periods (amenorrhea), which assists with maintaining functional stability during symptomatic phases. This low-dose hormonal strategy is relevant for patients seeking a contraceptive strategy that features a low-dose hormonal profile while remaining fully reversible.

Quick Fact: Support for Heavy Bleeding
The system may assist with a reduction in blood loss over time, supporting lighter, shorter periods for patients experiencing heavy menstrual symptoms.

Eligibility Map: Who Can and Cannot Use Kyleena — Official Regulatory Information

Kyleena's official regulatory profile defines eligibility for women seeking contraception for up to five years, including those who have or have not given birth (nulliparous and parous women).

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Pregnancy or suspicion of pregnancy; acute liver disease or liver tumor; known or suspected malignancy of the breast or reproductive organs; uninvestigated uterine bleeding; acute pelvic inflammatory disease (PID); or infected abortion in the past three months.
Age-related eligibility rules	Use is not indicated before menarche or in postmenopausal women. Safety and efficacy have not been studied in women over the age of 65 years.
Condition-specific eligibility rules	Hepatic Impairment: Contraindicated in acute disease; use in other cases not studied. Renal Impairment: Safety and efficacy not studied.
Pregnancy and lactation eligibility status	Pregnancy is a contraindication. Lactation is generally permitted, but insertion carries an increased risk of uterine perforation.
Eligibility-related restrictions	Insertion should not occur until a minimum of six weeks postpartum and is restricted in patients with a uterine anomaly that distorts the uterine cavity.

Official Eligibility Statements:

• Kyleena is contraindicated in women with a known or suspected pregnancy or progestin-sensitive cancer.
• Use is not indicated for pre-menarcheal or postmenopausal populations.
• Safety and efficacy are not established for use in women with renal or non-acute hepatic impairment.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use the medicine by listing absolute contraindications related to malignancy, active infection, and liver function. Eligibility is further structured by age-related exclusions and conditional use warnings concerning the timing of insertion and specific organ function limitations.

The official interaction profile for Kyleena is defined by its method of administration, which provides minimal systemic exposure to the active ingredient, levonorgestrel. This localized drug delivery significantly reduces the potential for systemic drug-drug interactions when compared to oral hormonal contraceptives.

A key regulatory finding addresses the interaction pattern with hepatic enzyme-inducing medicines. These include substances like the anti-infective Rifampicin and certain anticonvulsants (e.g., Phenytoin). While these drugs increase the clearance of hormones in the liver, official regulatory guidance confirms that the effectiveness of the Levonorgestrel IUS is not expected to be compromised by this effect. This means the mechanism of hepatic enzyme induction does not translate into a clinically significant interaction.

Consequently, the regulatory labeling for Kyleena includes no mandatory timing requirements or the need to separate the administration of the device from these medicines. Furthermore, the prescribing information states that interactions with food or herbal products, including St. John's wort, have not been established to be clinically relevant. The only major interaction-related constraint is the official contraindication against use in patients with acute liver disease or a liver tumor, which is noted due to the hormone’s primary metabolic clearance pathway.

The mechanism of action for Kyleena involves the highly localized, peripheral activity of the synthetic progestin Levonorgestrel (LNG). This biological activity is achieved through three synergistic domains operating directly within the female reproductive tract .

Modulation of Cervical Fluid Rheology

This domain involves the rapid, direct agonism of the Progesterone Receptor (PR) within the cervical glandular epithelium. This interaction alters the secretory pathway, causing the cervical mucus to become significantly thicker and less voluminous. The resulting physiological effect is the formation of a physical and chemical barrier that impedes sperm motility and transit into the uterus.

Endometrial Tissue Atrophy

LNG's local presence drives a strong progestogenic signal to the endometrial stromal cells and glands. This signal suppresses the normal cyclical proliferation pathway, inducing atrophy and decidualization of the tissue lining the uterus. The resulting physiological state is a suppressed, thin, non-secretory environment that fundamentally changes the conditions required for implantation.

Functional Inhibition of Sperm

This mechanism involves the localized interference of the high concentration of Levonorgestrel with the functional capability of the sperm. The progestin acts to inhibit key cellular processes, including sperm motility and capacitation (the maturation process needed for fertilization). This complementary effect results in reduced sperm function, thereby supporting the overall localized biological effect.

Kyleena is used solely through intrauterine administration, a process involving the insertion of a single device directly into the uterus. This highly specialized procedure must be performed using a strict aseptic technique by a trained healthcare provider in an outpatient setting. The device itself contains 19.5 mg of the active ingredient Levonorgestrel and constitutes the standard dose; no dose titration or adjustment is required after placement.

The single, one-time administration provides contraceptive coverage for up to five years (60 months). The system releases the hormone continuously over this duration, beginning at an initial rate that gradually declines over the period. To ensure optimal protection from the start, insertion is typically performed within the first seven days of the onset of menstrual bleeding. If insertion occurs outside this defined window, a non-hormonal back-up method must be used for seven days.

As a low-dose, localized hormonal system, the official labeling does not specify dose adjustments for systemic conditions such as hepatic or renal impairment. The system is approved for use in females of any age who can become pregnant. After the five-year duration, the system must be removed or replaced by a healthcare professional to maintain continuous usage. The product is supplied sterile, is for single use only, and cannot be re-loaded.

Kyleena: Recent Clinical Evidence

The efficacy and safety of the Kyleena levonorgestrel-releasing intrauterine system (LNG-IUS) were established through a multinational clinical program involving women aged 18 to 35 years. The device is authorized for the prevention of pregnancy for up to five years.

Efficacy and Continuation Rates

Clinical trials demonstrated a low pregnancy rate, calculated using the Pearl Index (PI). The cumulative five-year pregnancy rate observed in the primary study was approximately 1.45%, indicating a high level of effectiveness throughout the five-year duration. Real-world observational studies, such as the Kyleena Satisfaction Study (KYSS), have also reported high continuation rates, with over 80% of participants choosing to continue using the device after 12 months, irrespective of their age or previous contraceptive use.

Bleeding Profile

A key finding in the clinical evidence relates to changes in menstrual bleeding patterns. Initially, during the first three to six months of use, users commonly experience irregular bleeding, spotting, or an increased number of bleeding days. Over time, the bleeding profile typically improves. By the end of five years of use, study data showed that approximately 23% of participants experienced amenorrhea (absence of menstrual bleeding) and 26% experienced infrequent bleeding.

Bleeding Pattern (End of 5 Years)	Percentage of Users
Amenorrhea (No Bleeding)	sim 23%
Infrequent Bleeding	sim 26%

Adverse Events and Side Effects

The most common adverse events reported in clinical trials, occurring in over 5% of users, included vulvovaginitis, ovarian cysts, and abdominal or pelvic pain. Ovarian cysts, though frequently reported, are typically non-functional and resolve on their own. The most frequent adverse events that led to discontinuation of the device included increased bleeding, device expulsion, and pelvic pain. Serious adverse events, such as uterine perforation, pelvic inflammatory disease (PID), and ectopic pregnancy, occurred infrequently, though users should be aware of these potential risks.

Key Studies & References

1. Medical Eligibility Criteria for Contraceptive Use, 5th edition (WHO Guideline)

Common questions about Kyleena (FAQ)

---

Q: Is it possible to use tampons or menstrual cups after getting Kyleena placed?

Official product information indicates that both tampons and menstrual cups can be used while Kyleena is in place. Official guidance indicates that users should exercise care when removing these products to avoid accidentally pulling on the threads of the device.

---

Q: Can using Kyleena affect sex drive or libido?

Changes in sexual desire have been reported in clinical trials involving the levonorgestrel IUS class. Official product information notes that changes in sexual desire, including decreased libido, have been reported in postmarketing experience.

---

Q: What should be done if the IUD threads (strings) cannot be felt?

If the threads of the device cannot be felt, or if they seem longer or shorter than what is usual, this may be a sign the device has moved. Official information states that users should contact a healthcare provider promptly to have the position of the device checked.

---

Q: Can a partner feel the IUD strings during sexual intercourse?

Kyleena is inserted into the uterus, which means a partner should not feel the device itself. Regulatory documents indicate that the threads attached to the device may sometimes be felt by a partner during sexual intercourse.

---

Q: What factors might increase the risk of the IUD being expelled?

Regulatory documents state that the risk of the device being expelled from the uterus is higher if the insertion occurs immediately after childbirth. An increased risk is also suggested, based on limited data, if the device is inserted after a second-trimester abortion.

---

Q: If Kyleena is removed, how quickly can fertility return?

According to official patient information, the contraceptive effects of Kyleena are instantly reversible upon removal. Fertility levels are reported to rapidly return to what is considered normal for the individual user once the device is taken out.

---

Q: Is Kyleena designed to be used as emergency contraception?

No, Kyleena is not indicated for use as emergency contraception. Its official purpose, as defined in regulatory documents, is for long-term pregnancy prevention for a duration of up to five years.

---

Q: Does Kyleena offer any protection against sexually transmitted infections (STIs) or HIV?

The official patient counseling information clearly states that Kyleena does not protect against HIV or any other sexually transmitted infections (STIs). Additional methods, such as a barrier method, should be considered for protection against STIs.

---

Q: What are the specific conditions under which a person can have an MRI scan with Kyleena in place?

Kyleena is classified as "MR Conditional." This means that having an MRI is safe only if specific conditions are met, such as scanning at a static magnetic field of 3.0 T or less. It is generally stated that users should inform imaging staff that they have the device in place before undergoing the procedure.

---

Q: Can Kyleena cause changes in hair growth or hair loss?

Regulatory documents list changes in hair growth as possible adverse reactions. These changes may include hair loss, known as alopecia, or, conversely, excessive hair growth (hirsutism).

---

Q: How soon after insertion is a follow-up visit typically recommended?

Official patient guidelines recommend a follow-up visit with a healthcare provider. This visit is typically scheduled between 4 to 6 weeks after the device is placed to ensure that Kyleena is correctly positioned in the uterus.

---

Q: Is it normal to feel a change in energy level or experience fatigue after getting Kyleena?

Fatigue is listed among the commonly reported adverse events noted during clinical trials. This means that a change in energy level or feeling tired is a reported experience for some users.

---

Q: Is it common for Kyleena to cause vaginal dryness?

While vaginal dryness is not explicitly listed as an adverse reaction in official product information, other related effects are commonly reported. These adverse reactions include vulvovaginitis and changes in genital discharge.

---

Q: What are the potential signs that Kyleena may have moved out of position (expulsion)?

Potential signs that the device may have moved include experiencing severe cramping, increased or heavy bleeding, or being unable to feel the threads. If expulsion is suspected, regulatory information states that a back-up contraceptive method should be used and a healthcare provider should be immediately contacted.

---

Q: Can Kyleena be used by someone with a history of ectopic pregnancy?

Official warnings note that women with a previous history of ectopic pregnancy carry a higher risk of having another one. Official warnings state that a healthcare provider should carefully assess this risk before Kyleena insertion is considered.

Kyleena (levonorgestrel-releasing intrauterine system) storage and disposal instructions are defined by official regulatory requirements to maintain product integrity and safety.

---

Storage Conditions

Kyleena must be stored at controlled room temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The system is supplied in a sterile package and is for single use only. The sterile package should not be opened until needed for insertion, and the system must not be used if the blister is damaged or open.

---

Safety and Disposal

Kyleena must be kept out of the sight and reach of children.

It must not be inserted after the expiry date stated on the carton. Any unused product or waste material, including the used system, must be disposed of in accordance with local requirements. Used systems should be handled as biohazardous waste to prevent hormonal ingredients from entering water or sewer systems.